Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2029 versus octreotide LAR or lanreotide in gastroenteropancreatic neuroendocrine tumors
2021-000849-40Phase 3Active
- Sponsor
- Camurus
- Start
- Jun 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of octreotide hydrochloride, octreotide LAR and lanreotide in Gastroenteropancreatic Carcinoid Tumor (2 arms), sponsored by Camurus. Primary endpoint: Progression-free survival. Started Jun 2021; status: active.
02
Drugs
octreotide hydrochlorideoctreotide LARlanreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on 2021-000849-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000849-40.